|
|
|
|
| LEADER |
00000cam a2200000 7i4500 |
| 001 |
0000092120 |
| 005 |
20200311093000.0 |
| 008 |
170808s2016 enk eng |
| 020 |
|
|
|a 1849738289
|
| 020 |
|
|
|a 9781782622376
|
| 020 |
|
|
|a 9781849738286
|
| 040 |
|
|
|a UniSZA
|e rda
|
| 050 |
0 |
0 |
|a RM301.5
|b .N49 2016
|
| 060 |
1 |
0 |
|a QV 38
|b .N532 2016
|
| 090 |
0 |
0 |
|a RM301.5
|b .N49 2016
|
| 245 |
1 |
0 |
|a New horizons in predictive drug metabolism and pharmacokinetics
|c edited by Alan G. E. Wilson
|
| 264 |
|
1 |
|a Cambridge :
|b Royal Society of Chemistry
|c c2016
|
| 300 |
|
|
|a xxi, 422 pages :
|b illustration (some color) ;
|c 24 cm.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a unmediated
|2 rdamedia
|
| 338 |
|
|
|a volume
|2 rdacarrier
|
| 490 |
1 |
|
|a RSC drug discovery series
|v no 49
|
| 504 |
|
|
|a Includes bibliographical references and index
|
| 505 |
0 |
|
|a 1. How physicochemical properties of drugs affect their metabolism and clearance -- 2. Role of solubility, permeability and adsorption in drug discovery in development -- 3. Models for nonspecific binding and partitioning -- 4. Cytochrome P450 mediated drug metabolism -- 5. Non-cytochrome P450 enzymes and glucuronidation -- 6. Metabolite profiling -- 7. Application of humanised and other transgenic models to predict human responses to drugs -- 8. Stem cells and drug metabolism -- 9. Chemically reactive versus stable drug metabolites: Role in adverse drug reactions -- 10. Integrating metabolism and toxicity properties -- 11. Metabolomics-based approaches to determine drug metabolite profiles -- 12. Drug-drug ineteractions: regulatory and theoretical considerations, and an industrial perspective -- 13. Drug-drug interactions: Computational approaches -- 14. Induction of hepatic cytochrome P450 enzymes: Importance in drug development and toxicity -- 15. Current status and implications of transporters: QSAR analysis method to evaluate drug-drug interactions of human bile salt export pump (ABCB11/BSEP) and prediction of intrahepatic cholestasis risk -- 16. Formulation of optimizing bioavailability -- 17. Systems pharmacology modelling -- 18. Pharmacokinetic-pharmacodynamic modelling in drug development with special reference to oncology
|
| 650 |
|
0 |
|a Drug development
|
| 650 |
|
0 |
|a Drugs
|x Metabolism
|
| 650 |
|
0 |
|a Pharmacokinetics
|
| 650 |
|
2 |
|a Pharmaceutical Preparations
|x Metabolism
|
| 650 |
2 |
2 |
|a Biopharmaceutics
|
| 700 |
1 |
|
|a Wilson, Alan G. E. ,
|d 1947- ,
|e editor
|
| 999 |
|
|
|a 1000169170
|b Book
|c OPEN SHELF (30 DAYS)
|e Tembila Campus
|